Flow Medical Secures $5 Million Seed Funding to Advance Innovative Pulmonary Embolism Therapy

Chicago, IL – December 17, 2024 – Flow Medical, a pioneering company in pulmonary embolism (PE) treatment technology, today announced the closing of an oversubscribed $5 million seed funding round, which includes $2 million previously secured from friends and family. This investment positions Flow Medical to accelerate the development and launch of its PE device, with the goal of enhancing patient outcomes and advancing cardiovascular care.

The seed round was supported by a strategic group of investors with an interest in healthcare innovation, including the University of Chicago Medical Center as part of its UCM Ventures initiative. The funding represents UCM Ventures’ first direct investment in a med-tech startup. All three founders of Flow Medical are faculty members at the University of Chicago.

“This is the second company I have built out of UChicago, and I am thrilled to have such strong support from the investment community,” said Jennifer Fried, CEO of Flow Medical. “We are at the forefront of a new era in PE treatment and are poised to translate our innovative ideas into meaningful clinical advancements that can save lives.”

The use of the funds will focus on design verification and validation testing, initiating a first-in-human study, and establishing partnerships to ensure broad adoption and accessibility of their pioneering treatment platform. Flow Medical’s solutions are designed to address critical gaps in PE treatment, benefiting patients and healthcare providers.

“We see great potential for Flow Medical’s technology to enhance patient care and are excited to be part of this journey,” said Stephen Weber, MD, chief medical officer for the UChicago Medicine health system, which is anchored by the University of Chicago Medical Center.

For more information, please visit www.flowmedical.co

###

About Flow Medical: Flow Medical is dedicated to transforming care for pulmonary embolism through innovative therapeutic solutions that improve patient outcomes and streamline treatment. Based in Chicago, IL, the company is at the forefront of cardiovascular treatment innovation.